TY - STD TI - Li J, Qin SK, Xu RH, Yau TCC, Ma B, Pan HM, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–29. ID - ref1 ER - TY - JOUR AU - Algars, A. AU - Sundstrom, J. AU - Lintunen, M. AU - Jokilehto, T. AU - Kytola, S. AU - Kaare, M. PY - 2017 DA - 2017// TI - EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer JO - Int J Cancer VL - 140 UR - https://doi.org/10.1002/ijc.30507 DO - 10.1002/ijc.30507 ID - Algars2017 ER - TY - STD TI - Xu JM, Kim TW, Shen L, Sriuranpong V, Pan HM, Xu RH, et al. Results of a Randomized, Double- Blind, Placebo- Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol. 2018;36(4):350-+.  ID - ref3 ER - TY - JOUR AU - Alfonso, P. G. AU - Chaves, M. AU - Munoz, A. AU - Salud, A. AU - Garcia-Giron, C. AU - Gravalos, C. PY - 2012 DA - 2012// TI - Phase ii study to evaluate efficacy and safety of irinotecan, CAPECITABINE and bevacizumab in metastatic colorectal cancer (MCRC) patients JO - Ann Oncol VL - 23 ID - Alfonso2012 ER - TY - STD TI - Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol. 2013;14(2):125–33. ID - ref5 ER - TY - STD TI - Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(12):1351–60. ID - ref6 ER - TY - JOUR AU - Allegra, C. J. AU - Jessup, J. M. AU - Somerfield, M. R. AU - Hamilton, S. R. AU - Hammond, E. H. AU - Hayes, D. F. PY - 2009 DA - 2009// TI - American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.21.9170 DO - 10.1200/JCO.2009.21.9170 ID - Allegra2009 ER - TY - JOUR AU - Kang, M. J. AU - Hong, Y. S. AU - Kim, K. P. AU - Kim, S. Y. AU - Baek, J. Y. AU - Ryu, M. H. PY - 2012 DA - 2012// TI - Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status JO - Investig New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-011-9703-8 DO - 10.1007/s10637-011-9703-8 ID - Kang2012 ER - TY - JOUR AU - Konigsberg, R. AU - Hulla, W. AU - Klimpfinger, M. AU - Reiner-Concin, A. AU - Steininger, T. AU - Buchler, W. PY - 2011 DA - 2011// TI - Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal Cancer patients JO - Oncology VL - 81 UR - https://doi.org/10.1159/000334919 DO - 10.1159/000334919 ID - Konigsberg2011 ER - TY - JOUR AU - Li, W. AU - Shi, Q. AU - Wang, W. AU - Liu, J. AU - Ren, J. AU - Li, Q. PY - 2014 DA - 2014// TI - KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis JO - Color Dis VL - 16 UR - https://doi.org/10.1111/codi.12749 DO - 10.1111/codi.12749 ID - Li2014 ER - TY - JOUR AU - Riesco-Martinez, M. C. AU - Berry, S. R. AU - Ko, Y. J. AU - Mittmann, N. AU - Giotis, A. AU - Lien, K. PY - 2016 DA - 2016// TI - Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type KRAS Unresectable metastatic colorectal Cancer JO - J Oncol Pract VL - 12 UR - https://doi.org/10.1200/JOP.2015.008730 DO - 10.1200/JOP.2015.008730 ID - Riesco-Martinez2016 ER - TY - JOUR AU - Webster, J. AU - Kauffman, T. L. AU - Feigelson, H. S. AU - Pawloski, P. A. AU - Onitilo, A. A. AU - Potosky, A. L. PY - 2013 DA - 2013// TI - KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal Cancer in community settings JO - Cancer Epidemiol Biomark Prev VL - 22 UR - https://doi.org/10.1158/1055-9965.EPI-12-0545 DO - 10.1158/1055-9965.EPI-12-0545 ID - Webster2013 ER - TY - STD TI - Chen Y, Cao D, Bi F, Li Q, Qiu M. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in southwest Chinese population. Med Oncol. 2014;31(5). ID - ref13 ER - TY - JOUR AU - Deng, Y. H. AU - Cai, Y. AU - Lin, J. Y. AU - Jiang, L. AU - Hu, H. B. PY - 2015 DA - 2015// TI - Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence - a retrospective single-center study JO - Gastroenterol Rep VL - 3 ID - Deng2015 ER - TY - STD TI - Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077–85. ID - ref15 ER - TY - STD TI - Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, et al. Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010;28(19):3191–8. ID - ref16 ER - TY - JOUR AU - Feliu, J. AU - Safont, M. J. AU - Salud, A. AU - Losa, F. AU - Garcia-Giron, C. AU - Bosch, C. PY - 2010 DA - 2010// TI - Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer JO - Br J Cancer VL - 102 UR - https://doi.org/10.1038/sj.bjc.6605663 DO - 10.1038/sj.bjc.6605663 ID - Feliu2010 ER - TY - JOUR AU - Gervais, C. AU - Tournigand, C. PY - 2015 DA - 2015// TI - Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch colorectal Cancer group JO - Oncologie VL - 17 UR - https://doi.org/10.1007/s10269-015-2541-4 DO - 10.1007/s10269-015-2541-4 ID - Gervais2015 ER - TY - STD TI - Nakayama G, Ishigure K, Yokoyama H, Uehara K, Kojima H, Ishiyama A, et al. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902). BMC Cancer. 2017;17. ID - ref19 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Simi, L. AU - Pratesi, N. AU - Vignoli, M. AU - Sestini, R. AU - Cianchi, F. AU - Valanzano, R. PY - 2008 DA - 2008// TI - High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer JO - Am J Clin Pathol VL - 130 UR - https://doi.org/10.1309/LWDY1AXHXUULNVHQ DO - 10.1309/LWDY1AXHXUULNVHQ ID - Simi2008 ER - TY - STD TI - Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann KP, et al. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer. 2015;112(6):963–70. ID - ref22 ER - TY - JOUR AU - Rebersek, M. AU - Boc, M. AU - Cerkovnik, P. AU - Benedik, J. AU - Hlebanja, Z. AU - Volk, N. PY - 2011 DA - 2011// TI - Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis JO - Radiol Oncol VL - 45 UR - https://doi.org/10.2478/v10019-011-0039-y DO - 10.2478/v10019-011-0039-y ID - Rebersek2011 ER - TY - JOUR AU - Cserepes, M. AU - Ostoros, G. AU - Lohinai, Z. AU - Raso, E. AU - Barbai, T. AU - Timar, J. PY - 2014 DA - 2014// TI - Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy JO - Eur J Cancer VL - 50 UR - https://doi.org/10.1016/j.ejca.2014.04.001 DO - 10.1016/j.ejca.2014.04.001 ID - Cserepes2014 ER - TY - JOUR AU - Chen, H. H. AU - Lin, J. K. AU - Chen, J. B. AU - Chuang, C. H. AU - Liu, M. C. AU - Wang, J. Y. PY - 2018 DA - 2018// TI - Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial JO - Asia Pac J Clin Oncol VL - 14 UR - https://doi.org/10.1111/ajco.12692 DO - 10.1111/ajco.12692 ID - Chen2018 ER - TY - STD TI - Yamaguchi K, Taniguchi H, Komori A, Narita Y, Nitta S, Nomura M, et al. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. BMC Cancer. 2015;15. ID - ref26 ER - TY - STD TI - Naeim A, Ward PR, Wang HJ, Dichmann R, Liem AKD, Chan D, et al. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. J Geriatr Oncol. 2013;4(4):302–9 ID - ref27 ER - TY - JOUR AU - Adamo, V. AU - Festa, V. AU - Adamo, B. AU - Franchina, T. AU - Iorfida, M. AU - Maugeri, S. M. PY - 2007 DA - 2007// TI - Safety of the combination capecitabine plus bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience JO - Ann Oncol VL - 18 ID - Adamo2007 ER - TY - JOUR AU - Alahmari, A. K. AU - Almalki, Z. S. AU - Alahmari, A. K. AU - Guo, J. J. PY - 2016 DA - 2016// TI - Thromboembolic events associated with bevacizumab plus chemotherapy for patients with colorectal Cancer: a meta-analysis of randomized controlled trials JO - Am Health Drug Benefits VL - 9 ID - Alahmari2016 ER - TY - JOUR AU - Chen, X. X. AU - Chen, Y. F. AU - Cai, X. Y. AU - Zhang, D. S. AU - Fan, L. AU - Qiu, H. J. PY - 2017 DA - 2017// TI - Efficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: a meta-analysis JO - J Cancer Res Ther VL - 13 UR - https://doi.org/10.4103/jcrt.JCRT_405_17 DO - 10.4103/jcrt.JCRT_405_17 ID - Chen2017 ER - TY - JOUR AU - Nakayama, G. AU - Uehara, K. AU - Ishigure, K. AU - Yokoyama, H. AU - Ishiyama, A. AU - Eguchi, T. PY - 2012 DA - 2012// TI - The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801) JO - Cancer Chemother Pharmacol VL - 70 UR - https://doi.org/10.1007/s00280-012-1948-1 DO - 10.1007/s00280-012-1948-1 ID - Nakayama2012 ER - TY - STD TI - Simkens LHJ, van Tinteren H, May A, ten Tije AJ, Creemers GJM, Loosveld OJL, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385(9980):1843–52.  ID - ref32 ER - TY - STD TI - Cao RH, Zhang S, Ma DD, Hu LK. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. Med Oncol. 2015;32(1). ID - ref33 ER - TY - STD TI - Sugimachi K, Sakimura S, Kuramitsu S, Hirata H, Niida A, Iguchi T, et al. Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy. Br J Cancer. 2018;119(4):419–23. ID - ref34 ER -